



Notizie dalla coorte ICONA

Antonella Cingolani
Fondazione Policlinico A. Gemelli, IRCCS
Universita' Cattolica S. Cuore








Disclosures

A. Cingolani received speaker honorarium from Gilead Sciences, Janssen-Cilag, Merck and ViiV Healthcare.




Projected cancer incidence rates and burden among adult PLWH in the United States through 2030 (HIV/AIDS Cancer Match Study)

MS Shiels, Ann Intern Med 2018







Trajectories of comorbidities in HIV 2030: how prevalence of cancer will change?




PEARL model
Prevalence of anxiety, depression, stage .3 chronic kidney disease (CKD), dyslipidemia, diabetes, hypertension, cancer, end-stage liver disease (ESLD), myocardial infarction (MI) were forecasted through 2030. Simulations were informed by the US CDC HIV surveillance data of new HIV diagnosis and NA-ACCORD data on risk of comorbidities from 2009 to 2017.





22,049 Icona PWH

Number of PWH enrolled by calendar year




Demographic characteristics of 13,268 PWH at last follow up in 2021-2024

	n (%)		n (%)
Sex M	10626 (80%)	VL strata:	
Median age	49 (40-58)	<=50	10287 (90.5%)
Age >60	2528 (19%)	50-200	412 (3.6%)
Italians	10546 (79.4%)	200-1000	130 (1.1%)
Risk:		1000-10k	102 (0.8%)
Heterosexual contacts	5340 (40.2%)	10k-100k	168 (1.4%)
Homo/Bisexual contacts	6038 (45.5%)	>100k	257 (2.2%)
IDU/ex IDU	808 (6%)	Line:	
Other/Unknown	1082 (8.1%)	Naïve	211 (1.5%)
CD4 strata:		1st	3653 (27.5%)
<200	599 (5.2%)	2sd	2658 (20%)
<350	900 (7.9%)	>=3rd	6746 (50.8%)
		INSTI	9976 (75.1%)
		Median duration of HIV (years)	8.4 (3.4-14)



22,049 Icona PWH


Prevalence of born outside Italy by calendar period of enrolment






Mode of HIV transmission according to calendar period of enrolment

Born outside Italy
(n=4,509)




Born in Italy
(n=17,520)





22,049 Icona PWH


Age strata at enrolment according to calendar year of enrolment






Age strata and nationality according to calendar year of enrolment (2019 to 2023): ICONA cohort and ISS_CoA Registry

ICONA (n=3,887)





ISS-CoA (n=9,841)






22,049 Icona PWH

Recent infections, late presenters and advanced naive according to calendar period






Prevalence of non-communicable comorbidities by age strata at enrolment





Cumulative incidence of the novo malignancies (not including skin non-melanoma), according to gender and time since first HIV-positive test.




Fondazione Icona
ITALIAN COHORT NAIVE ANTIRETROVIRALS
Conceived by Professor Mauro Moroni

Piselli et al, in press




Cause of death, n=1,708





Incidence of non-AIDS-defining cancers among people living with HIV

92 publications arising from 46 independent studies including 7 articles out of 7 studies from developing countries






Standardized incidence ratios (SIR) and 95% confidence intervals (CI) for incident cancers according to gender. ICONA Cohort Study: Italy, 1997-2023

+

Type/Site	ICD-10 codes ¹	No. of cancer cases		SIR (95% CI)	No. of cancer cases Male/Female	SIR (95% CI)	
		Observed	Expected			Male	Female
Virus-related							
Anus	C21	32	1.5	21.0 (14.4-29.7)	31/1	27.6 (18.7-39.2)	NC
Liver	C22	25	16.4	1.5 (1.0-2.3)	21/4	1.4 (0.9-2.1)	3.8 (1.0-9.7)
Kaposi's sarcoma	C46	204	1.4	144.8 (125.6-166.1)	192/12	141.6 (122.2-163.1)	230.0 (118.9-401.8)
Invasive cervical cancer	C53	18	3.0	6.0 (3.6-9.5)	-/18	-	6.0 (3.6-9.5)
Penis	C60	3	1.0	3.1 (0.6-9.0)	3/-	3.1 (0.6-9.0)	-
Hodgkin lymphoma	C81	57	5.7	10.0 (7.6-13.0)	48/9	10.4 (7.7-13.8)	8.3 (3.8-15.8)
Non-Hodgkin Lymphomas (All types)	C82-85, C96	127	21.9	5.8 (4.8 -6.9)	109/18	5.9 (4.9-7.1)	5.1 (3.0-8.1)
Non virus-related							
Oral cavity	C00-10	11	9.8	1.1 (0.6-2.0)	10/1	1.1 (0.5-2.1)	NC
Esophagus	C15	7	3.6	1.9 (0.8-4.0)	5/2	1.5 (0.5-3.4)	NC
Stomach	C16	5	16.6	0.3 (0.1-0.7)	5/0	0.3 (0.1-0.8)	-
Colon-rectum	C18-20	24	51.3	0.5 (0.3-0.7)	21/3	0.5 (0.3-0.8)	0.4 (0.1-1.1)
Pancreas	C25	12	12.9	0.9 (0.5-1.6)	8/4	0.7 (0.3-1.5)	2.0 (0.5-5.1)
Larynx	C32	6	7.9	0.8 (0.3-1.7)	5/1	0.7 (0.2-1.5)	NC
Trachea, Bronchus and Lung	C33-34	66	50.3	1.3 (1.0-1.7)	52/14	1.2 (0.9-1.5)	2.6 (1.4-4.3)
Skin melanoma	C43	19	27.7	0.7 (0.4-1.1)	14/5	0.6 (0.4-1.1)	0.8 (0.3-1.9)
Other connective and soft tissue	C49	4	3.7	1.1 (0.3-2.8)	4/0	1.3 (0.4-3.4)	-
Breast, female	C50	29	43.3	0.7 (0.5-1.0)	-/29	-	0.7 (0.5-1.0)
Corpus uteri	C54	8	5.2	1.5 (0.7-3.0)	-/8	-	1.5 (0.7-3.0)
Ovary	C56	5	3.8	1.3 (0.4-3.1)	-/5	-	1.3 (0.4-3.1)
Prostate	C61	36	61.5	0.6 (0.4-0.8)	36/-	0.6 (0.4-0.8)	-
Testis	C62	9	11.5	0.8 (0.4-1.5)	9/-	0.8 (0.4-1.5)	-
Kidney	C64	15	20.6	0.7 (0.4-1.2)	14/1	0.8 (0.4-1.3)	NC
Bladder	C67	28	38.1	0.7 (0.5-1.1)	27/1	0.7 (0.5-1.1)	NC
Brain	C71	6	9.9	0.6 (0.2-1.3)	4/2	0.5 (0.1-1.2)	NC
Thyroid gland	C73	11	21.3	0.5 (0.3-0.9)	6/5	0.5 (0.2-1.1)	0.5 (0.2-1.2)
Multiple myeloma	C90	5	6.4	0.8 (0.3-1.8)	3/2	0.6 (0.1-1.6)	NC
Leukaemia	C91-92	8	12.1	0.7 (0.3-1.3)	7/1	0.7 (0.3-1.4)	NC
All, but non-melanoma skin cancers ^{2,3}		789	479.4	1.6 (1.5-1.8)	641/148	1.7 (1.6-1.9)	1.4 (1.2-1.6)




Fondazione Icona
ITALIAN COHORT NAIVE ANTIRETROVIRALS
Conceived by Professor Mauro Moroni

Piselli et al, in press



Comparison of age-specific cancer incidence rates by cancer types in the ICONA cohort vs the general population



Fondazione Icona
ITALIAN COHORT NAIVE ANTIRETROVIRALS
Conceived by Professor Mauro Moroni

Piselli et al, in press




CANCER RISK OF PEOPLE WITH HIV YOUNGER THAN 50 YEARS: ITALY, 1997-2023



Fondazione Icona
ITALIAN COHORT NAIVE ANTIRETROVIRALS
Conceived by Professor Mauro Moroni



Figure 1. Standardized incidence ratios (SIR) and 95% confidence intervals (CI) for incident cancers among People with HIV within 50 years of age, in the ICONA Cohort Study: Italy, 1997-2023.



Sites/types with <3 observed cases are not shown. ADMs: AIDS-defining malignancies; NADMs: Non AIDS-defining malignancies



Cumulative incidence of malignancies since initiation of combination anti-retroviral therapy (cART) according to CD4+ count. ICONA Cohort Study: Italy, 1997-2023.



Fondazione Icona
ITALIAN COHORT NAIVE ANTIRETROVIRALS
Conceived by Professor Mauro Moroni


Piselli et al, in press




Impact of cART on the incidence of defining and non-defining AIDS cancers among patients with HIV/AIDS

Twenty-one relevant articles involving more than 600,000 people with HIV/AIDS and 10,891 new cases of cancers.


Non AIDS defining malignancies




Kaposi sarcoma



Invasive cervical cancer



Non Hodgkin Lymphoma







Associations of HIV with lack of standard cancer treatment modality among people diagnosed with local-stage cancers in the United States (2001-2019), HIV/AIDS Cancer Match Study

Cancer Type	Standard Treatment Modality ^a	No. of PWH	No. of People Without HIV	PWH Not Receiving Standard Treatment, No. (%)	Persons Without HIV Not Receiving Standard Treatment, No. (%)	Calendar Years				P for Trend
						Overall	2001-2007	2008-2013	2014-2019	
						aOR ^b (95% CI)	aOR ^b (95% CI)	aOR ^b (95% CI)	aOR ^b (95% CI)	
Cervix	Surgery or radiation	558	49,474	26 (9.7)	1,028 (4.4)	2.33 (1.53 to 3.55)	2.42 (1.14 to 5.17)	1.41 (0.60 to 3.29)	3.57 (1.84 to 6.92)	.48
DLBCL	Chemotherapy	3,053	71,729	194 (27.9)	4,003 (19.6)	1.78 (1.48 to 2.14)	2.06 (1.53 to 2.77)	1.61 (1.20 to 2.17)	1.57 (1.06 to 2.32)	.32
HL	Chemotherapy	1,278	30,540	58 (31.0)	1,562 (25.3)	1.44 (1.04 to 2.00)	1.54 (0.89 to 2.69)	1.43 (0.85 to 2.40)	1.34 (0.68 to 2.64)	.15
Lung	Surgery or radiation	3,561	634,437	116 (19.0)	17,929 (12.4)	1.80 (1.46 to 2.22)	2.47 (1.63 to 3.76)	1.64 (1.15 to 2.32)	1.59 (1.13 to 2.23)	.0076
Anus	Radiation and chemotherapy	2,219	19,518	57 (4.5)	464 (4.6)	0.92 (0.66 to 1.28)	1.81 (1.00 to 3.25)	0.58 (0.32 to 1.06)	0.87 (0.50 to 1.50)	.0087
Prostate	Surgery or radiation	2,987	795,348	662 (27.3)	134,251 (20.2)	1.32 (1.21 to 1.45)	1.77 (1.40 to 2.23)	1.42 (1.23 to 1.63)	1.11 (0.97 to 1.27)	<.0001
Colon	Surgery	1,428	462,585	47 (8.4)	8,227 (4.3)	1.65 (1.23 to 2.23)	1.75 (0.91 to 3.36)	2.13 (1.41 to 3.22)	1.02 (0.55 to 1.89)	.0010
Breast	Surgery	1,250	817,324	32 (4.8)	16,264 (3.1)	1.62 (1.23 to 2.12)	3.35 (1.60 to 6.99)	1.75 (1.02 to 2.99)	0.68 (0.35 to 1.34)	<.0001



Innovative therapeutic anticancer treatment: how to include PWH?





Icona Foundation Study Group

BOARD OF DIRECTORS: A d'Arminio Monforte (President), A Antinori (Vice-President), S Antinori, A Castagna, R Cauda, G Di Perri, E Girardi, R Iardino, A Lazzarin, GC Marchetti, C Mussini, E Quiros-Roldan, L Sarmati, B Suligoi, F von Schloesser, P Viale.

SCIENTIFIC SECRETARY: A d'Arminio Monforte, A Antinori, A Castagna, F Ceccherini-Silberstein, A Cingolani, A Cozzi-Lepri, A Di Biagio, E Girardi, A Gori, S Lo Caputo, G Marchetti, F Maggiolo, C Mussini, M Puoti, CF Perno, C Torti.

STEERING COMMITTEE: A Antinori, A Bandera, S Bonora, A Calcagno, D Canetti, A Castagna, F Ceccherini-Silberstein, A Cervo, A Cingolani, P Cinque, A Cozzi-Lepri, A d'Arminio Monforte, A Di Biagio, R Gagliardini, A Giacomelli, E Girardi, N Gianotti, A Gori, G Guaraldi, S Lanini, G Lapadula, M Lichtner, A Lai, S Lo Caputo, G Madeddu, F Maggiolo, V Malagnino, G Marchetti, A Mondì, V Mazzotta, C Mussini, S Nozza, CF Perno, S Piconi, C Pinnetti, M Puoti, E Quiros Roldan, R Rossotti, S Rusconi, MM Santoro, A Saracino, L Sarmati, V Spagnuolo, N Squillace, V Svicher, L Taramasso, C Torti, A Vergori.

STATISTICAL AND MONITORING TEAM: A Cozzi-Lepri, S De Benedittis, I Fanti, M Giotta, C Marelli, A Rodano', A Tavelli.

COMMUNITY ADVISORY BOARD: M Cernuschi, L Cosmaro, A Perziano, V Calvino, D Russo, M Farinella, N Policek, VL Del Negro.

BIOLOGICAL BANK INMI AND SAN PAOLO: M Augello, S Carrara, S Graziano, G Prota, S Truffa, D Vincenti, R Rovito, M Sgarlata.

PARTICIPATING PHYSICIANS AND CENTERS: Italy A Giacometti, A Costantini, V Barocci (Ancona); A Saracino, C Santoro, E Milano (Bari); L Comi, C Suardi (Bergamo); P Viale, L Badia, S Cretella (Bologna); EM Erne, A Pieri (Bolzano); E Quiros Roldan, E Focà (Brescia); B Menzaghi, C Abeli (Busto Arsizio); L Chessa, F Pes (Cagliari); P Maggi, L Alessio (Caserta); G Nunnari, BM Celesia (Catania); J Vecchiet, K Falasca (Chieti); A Pan, S Dal Zoppo (Cremona); D Segala (Ferrara); F Bartalesi, A Bartoloni, B Borchì, C Costa (Firenze); S Lo Caputo, S Ferrara (Foggia); M Bassetti, E Pontali, S Bianchi, N Bobbio (Genova); C. Del Borgo, R. Marocco, G. Mancarella (Latina); S Piconi, C Molteni (Lecco); S Rusconi, G Canavesi (Legnano); G Pellicanò (Messina); G Marchetti, S Antinori, A Gori, M Puoti, A Castagna, A Bandera, V Bono, MV Cossu, A Giacomelli, R Lolatto, MC Moioli, L Pezzati, S Diotallevi, C Tincati (Milano); C Mussini, M Menozzi (Modena); P Bonfanti, G Lapadula (Monza); V Sangiovanni, I Gentile, V Esposito, N Coppola, FM Fusco, G Di Filippo, V Rizzo, N Sangiovanni, S Martini (Napoli); AM Cattelan, D Leoni (Padova); A Cascio, M Trizzino (Palermo); D Francisci, E Schiaroli (Perugia); G Parruti, F Sozio (Pescara); D Messeri, SI Bonelli (Pistoia); C Lazzaretti, R Corsini (Reggio Emilia); A Antinori, R Cauda, C Mastroianni, L Sarmati, A Latini, A Cingolani, I Mastrorosa, S Lamonica, M Capozzi, M Camici, I Mezzaroma, M Rivano Capparuccia, G Iaiani, C Stingone, L Gianserra, J Paulicelli, MM Plazzi, G d'Ettore, M Fusto, M Lichtner (Roma); I Coledan (Rovigo); G Madeddu, A De Vito (Sassari); M Fabbiani, F Montagnani (Siena); A Franco, R Fontana Del Vecchio (Siracusa); D Francisci, C Di Giuli (Terni); GC Orofino, G Calleri, G Di Perri, S Bonora, G Accardo (Torino); C Tascini, A Londero (Udine); G Battagin, S Nicolè (Vicenza); G Starnini, S Dell'Isola (Viterbo).